Merck Shares Outstanding 2010-2024 | MRK

Merck shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Merck shares outstanding for the quarter ending September 30, 2024 were 2.541B, a 0.2% decline year-over-year.
  • Merck 2023 shares outstanding were 2.547B, a 0.2% increase from 2022.
  • Merck 2022 shares outstanding were 2.542B, a 0.16% increase from 2021.
  • Merck 2021 shares outstanding were 2.538B, a 0.12% decline from 2020.
Merck Annual Shares Outstanding
(Millions of Shares)
2023 2,547
2022 2,542
2021 2,538
2020 2,541
2019 2,580
2018 2,679
2017 2,748
2016 2,787
2015 2,841
2014 2,928
2013 2,996
2012 3,076
2011 3,094
2010 3,120
2009 2,273
Merck Quarterly Shares Outstanding
(Millions of Shares)
2024-09-30 2,541
2024-06-30 2,544
2024-03-31 2,544
2023-12-31 2,547
2023-09-30 2,546
2023-06-30 2,539
2023-03-31 2,551
2022-12-31 2,542
2022-09-30 2,542
2022-06-30 2,540
2022-03-31 2,537
2021-12-31 2,538
2021-09-30 2,536
2021-06-30 2,540
2021-03-31 2,541
2020-12-31 2,541
2020-09-30 2,538
2020-06-30 2,536
2020-03-31 2,547
2019-12-31 2,580
2019-09-30 2,572
2019-06-30 2,588
2019-03-31 2,603
2018-12-31 2,679
2018-09-30 2,678
2018-06-30 2,696
2018-03-31 2,710
2017-12-31 2,748
2017-09-30 2,727
2017-06-30 2,752
2017-03-31 2,766
2016-12-31 2,787
2016-09-30 2,786
2016-06-30 2,789
2016-03-31 2,795
2015-12-31 2,841
2015-09-30 2,836
2015-06-30 2,850
2015-03-31 2,865
2014-12-31 2,928
2014-09-30 2,911
2014-06-30 2,949
2014-03-31 2,971
2013-12-31 2,996
2013-09-30 2,960
2013-06-30 3,010
2013-03-31 3,053
2012-12-31 3,076
2012-09-30 3,079
2012-06-30 3,072
2012-03-31 3,074
2011-12-31 3,094
2011-09-30 3,091
2011-06-30 3,110
2011-03-31 3,104
2010-12-31 3,120
2010-09-30 3,102
2010-06-30 3,125
2010-03-31 3,141
2009-12-31 2,273
2009-09-30 2,114
2009-06-30 2,110
2009-03-31 2,109
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $258.017B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $765.281B 79.27
Novo Nordisk (NVO) Denmark $492.372B 37.58
Johnson & Johnson (JNJ) United States $380.982B 15.45
AbbVie (ABBV) United States $354.099B 18.65
Novartis AG (NVS) Switzerland $225.903B 15.02
AstraZeneca (AZN) United Kingdom $221.475B 19.73
Pfizer (PFE) United States $157.307B 10.76
Sanofi (SNY) $134.378B 12.17
Innoviva (INVA) United States $1.211B 6.72